By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1111 Main Street
Suite 660
Vancouver  Washington  98660  U.S.A.
Phone: 360-980-8524 Fax: 360-980-8549



Company News
CytoDyn (CYDY) Submits Orphan Drug Application To FDA For Pretreatment With PRO 140 Of Treatment-Naïve HIV Patients 7/21/2016 12:53:29 PM
CytoDyn (CYDY) Submits Protocol for Phase IIb Trial for Treatment Naïve HIV Patients 7/19/2016 8:07:28 AM
CytoDyn (CYDY) Announces Investment Community Conference Call For July 13, 2016 7/11/2016 8:19:33 AM
ASM Microbe 2016 Presentation of Clinical Results From CytoDyn (CYDY)’s Phase IIb Monotherapy Extension Study Now Available 6/22/2016 7:43:22 AM
CytoDyn (CYDY)n’s PRO 140 Phase IIb HIV Monotherapy Trial Findings To Be Presented At ASM Microbe 2016 Conference On June 20 6/17/2016 8:08:47 AM
CytoDyn (CYDY) To Present At LD Micro Invitational Conference On June 7 6/2/2016 10:27:21 AM
Investors Aren't Impressed as Charlie Sheen Reveals He Wants in on Tiny CytoDyn (CYDY)'s HIV Drug Trial 2/12/2016 6:26:40 AM
CytoDyn Release: Uncontrolled Viral Loads: Experienced Patients Face Dwindling Pool Of Effective Options 1/28/2016 9:55:05 AM
CytoDyn Reports HIV-Patients Approaching 17 Months Of Complete Viral Suppression With PRO 140 Monotherapy 1/19/2016 10:31:52 AM
CytoDyn Release: Fighting GvHD And HIV At Same Time; Approval Of New Medical Discovery Expected In 2017 12/4/2015 2:29:52 PM